Health and Science Highlights - East County Magazine

• The global anti-infective drugs market is projected to reach a valuation of USD 187.5 billion by 2035. • Growth is primarily driven by the increasing global burden of bacterial, viral, fungal, and parasitic infections, alongside the critical emergence of antimicrobial resistance.

• The U.S. Department of Health and Human Services (HHS) announced a new policy on Tuesday banning federal funding for "dangerous" gain-of-function research. • This type of research involves enhancing viruses to predict potential threats, a practice that has faced scrutiny following the COVID-19 pandemic.

• An Ebola outbreak in the Democratic Republic of the Congo has surged to 3,200 confirmed cases and 1,405 deaths, marking the fastest growth rate ever recorded for any Ebola outbreak. • The crisis is exacerbated by a strike of healthcare workers who have walked off the job due to unpaid wages, severely hindering the medical response.

• A new study published in the Journal of Clinical Investigation reveals that losing specific healthy body fat can increase the risk of diabetes and fatty liver disease. • Researchers focused on familial partial lipodystrophy type 2 (FPLD2), a rare condition caused by a mutation in the lamin A/C gene that leads to fat loss in certain body areas.

• MedPage Today has compiled a series of health updates, including the release of Dr. Anthony Fauci's diaries and a recall of cold brew coffee. • Food safety experts are warning that federal budget cuts have hindered the ability to detect and stop the spread of potentially deadlier foodborne illness outbreaks.

• Morning Rounds reports on a variety of health updates, including the release of Dr. Anthony Fauci's diaries from the COVID-19 pandemic era. • The report highlights critical concerns regarding a potential global resurgence of HIV and new data tracking substance use trends across the United States.

• Prediction markets such as Kalshi and Polymarket are now allowing users to wager money on the outcomes of drug approvals. • Kalshi is further expanding these offerings by planning to enable betting on the specific results of clinical trials.

• An FDA advisory committee is meeting this week to review applications for novel peptide therapies that were previously rejected by former agency officials. • Affiliates of the American Academy of Peptide Medicine allege the FDA ignored critical safety and efficacy data, while industry and consumer advocates warn that approval would bypass traditional drug regulations.

• The FDA has raised concerns regarding the efficacy of Capricor Therapeutics' treatment for Duchenne muscular dystrophy ahead of an upcoming advisory committee hearing. • The agency's skepticism contradicts claims made by Capricor regarding the clinical benefits of the rare disease drug.

• FDA advisers voted to ease restrictions on popular peptides, potentially allowing specialized pharmacies to produce these compounds within the United States. • The decision comes despite agency concerns that these peptides lack the large, well-controlled human clinical trials required to establish safety and effectiveness for formal drug approval.

• Members of an FDA committee expressed concerns regarding the agency's decision to allow pharmacies to dispense certain medications without requiring traditional clinical trials. • Committee member Todd Durham, senior vice president at the Foundation Fighting Blindness, voted against adding specific peptides to the approved list.